Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Monopar Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MNPR
Nasdaq
8731
https://www.monopartx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Monopar Therapeutics Inc
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
- May 9th, 2024 11:00 am
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
- Apr 18th, 2024 12:00 pm
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
- Apr 16th, 2024 12:00 pm
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
- Apr 10th, 2024 12:00 pm
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
- Apr 4th, 2024 1:55 pm
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
- Apr 3rd, 2024 4:00 pm
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
- Mar 28th, 2024 11:00 am
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
- Mar 5th, 2024 12:00 pm
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
- Feb 27th, 2024 12:00 pm
Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation
- Feb 27th, 2024 10:40 am
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
- Feb 22nd, 2024 12:00 pm
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
- Feb 20th, 2024 1:00 pm
Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs
- Nov 9th, 2023 1:37 pm
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
- Nov 9th, 2023 12:00 pm
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
- Nov 1st, 2023 11:00 am
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
- Oct 10th, 2023 11:00 am
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 11:00 am
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
- Aug 10th, 2023 11:00 am
Monopar Provides Encouraging Camsirubicin Clinical Data Update
- Aug 8th, 2023 11:00 am
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
- Jul 11th, 2023 11:00 am
Scroll